Developing Cancer Cures through the ASX | Going Public w Leslie Chong & Paul Hopper

Imugene Ltd (ASX: IMU) is excited to share the 12th episode of 'Going Public' on Australia's leading investing platform. This monthly series offers unique access to the entrepreneurs, founders, and executives who have taken their businesses public.
In this episode, we delve into the remarkable journey of Imugene, a clinical-stage immuno-oncology company revolutionising cancer treatment with cutting-edge immunotherapies. CEO Leslie Chong shares how Imugene has transformed from a single-technology startup into a biotech leader with five active clinical trials targeting various cancers. We explore the strategic moves that propelled our market cap from $10 million to $500 million and secured our place in the ASX Top 300. You'll also hear from Executive Chairman Paul Hopper, the visionary behind our ASX listing and the successful IPOs of Radiopharm (RAD) and Chimeric (CHM). This episode offers invaluable insights into the world of biotech, innovation, and the path to IPO success. Join us for an in-depth look at Imugene's journey and achievements.
Listen on Spotify: open.spotify.c...
Listen on Apple Music: podcasts.apple...

[@Sebastian80-ew1jn]

Man this was kind of disappointing, I know it's under wraps most likely but I was hoping we'd hear updates. There are a not insignificant people that are looking to imugene oncolytic as their last hope. Any update on ORR or just FDA track would be a sigh of relief but I guess it won't be for another 10 years if we're lucky. Sad.